Zimmer Biomet (ZBH)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
$98.07-0.86%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · ZBH
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -19.8% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 3.5% |
Growth built into the price is above our model estimate.
The price assumes 23.4 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
ZBH — credit agreement
Dated 2026-06-29
Entry into a Material Definitive Agreement. On June 26, 2026, Zimmer Biomet Holdings, Inc. (the “Company”) entered into a new five-year revolving credit agreement and a new 364-day revolving credit agreement, as described below. The Five-Year Revolving Credit Agreement, dated as of June 26, 2026, among the Company, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the “Five-Year Credit Agreement”), is a five-year unsecured revolving facility of $1.5 billion (th…
Why it matters: Changes in EPS guidance show how confident management is about future earnings. This affects how investors feel.
Watch forManagement raises adjusted EPS guidance for 2026. It is now above $8.59.
Also watch forManagement lowers adjusted EPS guidance for 2026. It is now below $8.40.
Why it matters: Updates about the CFO change show that financial management is stable. This helps build investor trust.
Watch forA new CFO is announced. They have relevant experience and a positive vision for the company.
Also watch forNo news about the CFO transition creates uncertainty.
Why it matters: Missing this target shows problems in operations. It might also hurt investor confidence.
Worry ifQ2 2026 earnings per share reported below $1.22.
Less concerning ifQ2 2026 earnings per share reported above $1.30.
Why it matters: More share buybacks can show confidence in the company's finances. This can help share prices.
Supportive ifCompany announces share buybacks of more than $500 million in 2026.
Worry ifNo new share buyback announcements or cuts to the expected buyback amount.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$121 on $10,000 · ±1.2% | How much price usually moves either way. |
| Bad day | $251 loss on $10,000 · 2.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,415 loss on $10,000 · 24.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: High adoption rates of new products can drive revenue growth and market share.
Watch forNew products achieve adoption rates above 20% in Q2.
Also watch forNew products see adoption rates below 10% in Q2.
Why it matters: Completing the share buyback shows good use of money. It may help stock price.
Supportive ifZimmer Biomet completes $1 billion in share repurchases by the end of 2026.
Worry ifThe company does not complete the planned share buybacks or cuts the amount.
Why it matters: A smooth CFO transition is key for financial stability and trust from investors.
Watch forManagement says the transition will go smoothly. There will be no problems with reports.
Also watch forBig delays or problems reported during the CFO transition.
Why it matters: Hitting this target shows good use of money and trust in the business.
Supportive ifCompletion of share repurchases totaling $500 million or more by the end of Q3 2026.
Worry ifShare repurchases fall below $250 million by the end of Q3 2026.
Why it matters: Finishing this study is important for future products and market plans.
Supportive ifThey announced that the mBôs clinical study is complete.
Worry ifStudy completion is delayed or the results are not good.
Why it matters: A CFO transition could affect financial strategy and guidance. This may create uncertainty for investors.
Watch forNew CFO provides a positive outlook on financial guidance in the next earnings call.
Also watch forThe new CFO points out problems or lowers financial guidance.
Why it matters: Any further increase in EPS guidance signals strong earnings momentum. This could boost investor confidence.
Supportive ifManagement raises adjusted EPS guidance to more than $8.59.
Worry ifManagement lowers adjusted EPS guidance to less than $8.40.
Why it matters: If this growth rate is met, it shows strong market demand. It also shows good strategy execution.
Supportive ifQ3 revenue growth reported above 4.9%.
Worry ifQ3 revenue growth reported below 2.5%.
Why it matters: More share repurchases show management believes in the company's future. This can help the stock price.
Supportive ifThey announced share repurchases of more than $1 billion.
Worry ifThere are no announcements of share repurchases or plans to cut them.
Why it matters: New product approvals can drive sales growth and improve market position. This is crucial for long-term success.
Supportive ifFDA approves the new ROSA® Shoulder System.
Worry ifDelay or denial of FDA approvals for key products.